Adverse events in patients with castration-resistant prostate cancer treated with ra-223: a retrospective pharmacovigilance study

Background Radium-223 (Ra-223) received U.S. Food and Drug Administration (FDA) approval for treating castration-resistant prostate cancer with symptomatic bone metastases, excluding visceral metastases. Despite this, the safety profile of Ra-223 in large-scale, population-based use still needs to be explored.